Gramegna, Andrea
Aliberti, Stefano https://orcid.org/0000-0002-0090-4531
Confalonieri, Marco
Corsico, Angelo
Richeldi, Luca
Vancheri, Carlo
Blasi, Francesco
Article History
Received: 30 July 2018
Accepted: 25 September 2018
First Online: 8 October 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AG reports personal fees from Boehringer Ingelheim, Chiesi Farmaceutici, Vertex Spa. SA reports grant support from AstraZeneca, Bayer Healthcare, Grifols, Pfizer Ltd. and GlaxoSmithKline. AC has received payments for board membership, income for lectures, or support for research in respiratory disease from the following organizations: Astra Zeneca SPA, Boehringer Ingelheim Italia SPA, GlaxoSmithKline S.p.A., Grifols Italia S.P.A., Meda Pharma, Novartis Farma S.p.A., Stallergenes Italia S.r.l, CSL Behring SpA, A. Menarini Industrie Farmaceutiche Riunite Srl. LR reports personal fees from Medimmune, Biogen, Sanofi-Aventis, Takeda, ImmuneWorks, Shionogi, Cipla, Pliants Therapeutics, Boehringer Ingelheim, Roche. CV participated as a consultant, speaker and investigator for Actelion, Boehringer Ingelheim, Gilead, InterMune Inc. and Roche. FB reports research grants from Boehringer Ingelheim, Chiesi, Zambon, and Pfizer, congress lecture fees from Boehringer Ingelheim, Guidotti-Malesci, Menarini, GSK, Chiesi, Pfizer and Novartis, and consultancy fees from AstraZeneca, Menarini, Mundipharma, Novartis, GSK, Teva and Pfizer. FB is Editor-in-Chief of <i>Multidisciplinary Respiratory Medicine</i>, whereas SA, AC and LR are Associate Editors of <i>Multidisciplinary Respiratory Medicine.</i>
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.